Monarch therapeutics and snap biosciences, inc., a subsidiary of coeptis therapeutics holdings inc., enter licensing agreement to bolster snap-car nk cell therapy in oncology

Wexford, pa. and princeton, n.j., may 28, 2025 (globe newswire) -- snap biosciences, inc a majority-owned subsidiary of coeptis therapeutics holdings inc. (nasdaq: coep) and monarch therapeutics inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of snap biosciences' proprietary snap-car nk cell therapy platform in oncology using monarch's small molecule adaptor technology.
CAR Ratings Summary
CAR Quant Ranking